The best part about being a buy-and-hold investor is that when volatility strikes and analysts and pundits are panicking, you can calmly go about your business and steal great companies at bargain prices. One of the stocks on my top watchlist is Incyte (NASDAQ:INCY), which is a growing biotech company focused on developing oncology and anti-inflammatory drugs. The company's shares have recently fallen below $20 for the first time since early February, which I think warrants a deeper look. In the following video, I'll break down the pros and cons of adding Incyte to your portfolio, although I think the company has a lot of potential in its pipeline.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.